## Anna Wasiuk

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/7224109/anna-wasiuk-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

9 papers 1,477 6 h-index g-index

12 papers 1,796 pext. papers ext. citations avg, IF L-index

| # | Paper   | IF   | Citations |
|---|---|------|-----------|
| 9 | The mechanism of anti-tumor immunity induced by varlilumab, a CD27 agonist mAb, is model dependent <b>2015</b> , 3, P188  |      | 1         |
| 8 | Abstract 253: Synergistic antitumor activity of PD-1 signaling blockade and CD27 costimulation correlates with enhanced ratio of effector to regulatory T cells at the tumor site <b>2015</b> , |      | 3         |
| 7 | Tryptophan hydroxylase-1 regulates immune tolerance and inflammation. <i>Journal of Experimental Medicine</i> , <b>2012</b> , 209, 2127-35  | 16.6 | 96        |
| 6 | Mast cells impair the development of protective anti-tumor immunity. <i>Cancer Immunology, Immunotherapy</i> , <b>2012</b> , 61, 2273-82  | 7.4  | 32        |
| 5 | VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. <i>Journal of Experimental Medicine</i> , <b>2011</b> , 208, 577-92                                      | 16.6 | 388       |
| 4 | Mast Cells in Allergy and Tumor Disease <b>2010</b> , 137-158   |      | 6         |
| 3 | Molecular mechanism and function of CD40/CD40L engagement in the immune system. <i>Immunological Reviews</i> , <b>2009</b> , 229, 152-72  | 11.3 | 827       |
| 2 | Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines. <i>Blood</i> , <b>2008</b> , 111, 3116-25                                | 2.2  | 79        |
| 1 | Dendritic cells require the NF-kappaB2 pathway for cross-presentation of soluble antigens. <i>Journal of Immunology</i> , <b>2008</b> , 181, 354-63   | 5.3  | 45        |